KOURTNEY UMPHFRES: Open Payments
NPI 1528028321 · EXETER, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$300 in 17 payments from 8 companies in 2025. Trend: 2023 $683 · 2024 $612 · 2025 $300
Food & beverage: $300
| Company | Payments | Amount |
|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, Inc. | 7 | $109 |
| Lilly USA, LLC | 3 | $59 |
| Novo Nordisk Inc | 2 | $41 |
| AstraZeneca Pharmaceuticals LP | 1 | $25 |
| ABBVIE INC. | 1 | $20 |
| Abbott Laboratories | 1 | $16 |
| TOLMAR, INC. | 1 | $15 |
| Paratek Pharmaceuticals, Inc. | 1 | $13 |
Products named: JARDIANCE, MOUNJARO, Ozempic, FARXIGA, CREON, ID NOW INSTRUMENT, JATENZO, NUZYRA.
Industry payments across CA — which companies pay providers there.
